Reports Highlight Diet and Anemia Management

Two Nephrology TreatmentTrends™ publications released late last year analyze the market trends of products that help nephrologists and renal dietitians manage their patients’ renal anemia, hyperphosphatemia, and secondary hyperparathyroidism. The reports, issued by BioTrends Research Group, are based on survey results from 204 nephrologists and 201 renal dietitians in the United States.

The reports noted that renal dietitians (RDs) are integral to the management of dialysis patients, reinforcing patient adherence in taking phosphate binders, active Vitamin D, and agents that mimic calcium (calcimimetics).

Nephrologists are split regarding their first-line preference of agent in treating dialysis patients. Approximately half of nephrologists choose a calcium-based binder and half choose a non-calcium based binder, compared with more than two-thirds of RDs who choose to start with a non-calcium based binder. Seventy-three percent of nephrologists prefer to start with calcium-based binders in patients with chronic kidney disease who are not on dialysis.

In the parathyroid hormone modifier market, RDs report a high level of influence in the choice of Vitamin D product used. Nephrologists continue to use oral calcitriol most often.

In the renal anemia market, nephrologists are pursuing new treatment standards, such as lower target hemoglobin levels, lower levels for ESA (erythropoiesis-stimulating agent) initiation, holds, and dose reductions. More than two-thirds do not anticipate making any additional changes to their use of ESAs in chronic kidney disease or dialysis. Bundling will have an impact on ESA use, most likely through shifts to subcutaneous dosing and less aggressive treatment of EPO hypo-responders. New ESAs in development could also shift market dynamics, the report stated.